spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

TAT 2018 – Targeted Anticancer Therapies

European Society for Medical Oncology (ESMO)

5-7 March 2018
Paris Marriott Rive Gauche Hotel & Conference Centre

The constant evolution of early phase development and translational research drove ESMO to enrich its meeting portfolio by acquiring the TAT Congress and providing a discussion platform focusing on new molecular targets and innovative cancer therapeutics.

A prestigious scientific committee, led jointly by G. Giaccone and J. Tabernero, designed a cutting-edge programme, establishing the TAT 2018 Congress as the premier international anticancer drug development meeting bringing together academia, industry, clinicians, researchers, scientists and regulators.

The goals and the design of phase 1 studies have changed from just safety/toxicity to now include clinical activity/response and biomarker research. This new phase 1 paradigm has already led to rapid, conditional, approval of several new cancer therapeutics showing outstanding clinical activity in early-phase studies.

TAT focuses on early-phase development and translational research. The programme will cover targeted agents, immuno-oncology and combinations involving such agents. We hope to see you at TAT 2018!

phone +41 (0)91 973 19 00
email esmo@esmo.org
web www.esmo.org
 
Print this page
Send to a friend
   
Banner of Bio Trinity_Events_Page on Samedan
spacer
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>


News and Press Releases

International biomed specialist appoints WHP to deliver key expansion project

New state of the art cleanroom facilities will enable a leading international gene and cell therapy company to expand its bioprocessing operations and manufacturing capabilities.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement